Longevity science
87.1K views | +0 today
Follow
Longevity science
Live longer in good health and you will have a chance to extend your healthy life even further
Your new post is loading...
Your new post is loading...
Scooped by Ray and Terry's
Scoop.it!

Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors, study suggests

Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors, study suggests | Longevity science | Scoop.it

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

 

The findings, presented June 15, 2013, at the annual Endocrine Society meeting in San Francisco, indicate that the drug bazedoxifene packs a powerful one-two punch that not only prevents estrogen from fueling breast cancer cell growth, but also flags the estrogen receptor for destruction.

 

 

No comment yet.
Scooped by Ray and Terry's
Scoop.it!

Study shows Vitamin C intake protects (animal subjects) from bone loss: PLOS ONE

Epidemiologic studies correlate low vitamin C intake with bone loss. The genetic deletion of enzymes involved in de novo vitamin C synthesis in mice, likewise, causes severe osteoporosis. However, very few studies have evaluated a protective role of this dietary supplement on the skeleton.

 

Study authors show that the ingestion of vitamin C prevents the low-turnover bone loss following ovariectomy in mice. [They] show that this prevention in areal bone mineral density and micro-CT parameters results from the stimulation of bone formation, demonstrable in vivo by histomorphometry, bone marker measurements, and quantitative PCR.

 

Notably, the reductions in the bone formation rate, plasma osteocalcin levels, and ex vivo osteoblast gene expression 8 weeks post-ovariectomy are all returned to levels of sham-operated controls.

 

The study establishes vitamin C as a skeletal anabolic agent.

 

 

No comment yet.